PI3Kα Pathway Inhibition With Doxorubicin Treatment Results in Distinct Biventricular Atrophy and Remodeling With Right Ventricular Dysfunction

BACKGROUND: Cancer therapies inhibiting PI3Kα (phosphoinositide 3‐kinase‐α)–dependent growth factor signaling, including trastuzumab inhibition of HER2 (Human Epidermal Growth Factor Receptor 2), can cause adverse effects on the heart. Direct inhibition of PI3Kα is now in clinical trials, but the ef...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Am Heart Assoc
Auteurs principaux: McLean, Brent A., Patel, Vaibhav B., Zhabyeyev, Pavel, Chen, Xueyi, Basu, Ratnadeep, Wang, Faqi, Shah, Saumya, Vanhaesebroeck, Bart, Oudit, Gavin Y.
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2019
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512135/
https://ncbi.nlm.nih.gov/pubmed/31039672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.118.010961
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires